ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P42-22 Mental Health and Substance Use Disorder Provider Survey
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2022
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 1621 - 1630 လၢ 3563 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Autism Spectrum Disorder (ASD) Signs, Screening, and Resources
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-com-pharmprogpolicynotifctn-final-eff-8-1-22.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
m06718r02-provider-feedback-form-fillable-enabled.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP52-22 Learn to Live – An Online Behavioral Health Resource for Select Blue Cross and Blue Shield of Minnesota Health Plan Members
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 22, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP54-22 Update for New to Market Medical Drugs: betibeglogene autotemcel
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 22, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP39-22 Required Notification of Medicare Organization Determination Request Dismissal and Withdrawal
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 08, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP46-22 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective July 28, 2022
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 08, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP47-22 Medical Drug Management Update – Alpha-1 Proteinase Inhibitors
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 08, 2022